Cargando…

Efficacy and Safety of Switching From the DPP-4 Inhibitor Sitagliptin to the Human GLP-1 Analog Liraglutide After 52 Weeks in Metformin-Treated Patients With Type 2 Diabetes: A randomized, open-label trial

OBJECTIVE: To assess the efficacy and safety of switching from sitagliptin to liraglutide in metformin-treated adults with type 2 diabetes. RESEARCH DESIGN AND METHODS: In an open-label trial, participants randomized to receive either liraglutide (1.2 or 1.8 mg/day) or sitagliptin (100 mg/day), each...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pratley, Richard E., Nauck, Michael A., Bailey, Timothy, Montanya, Eduard, Filetti, Sebastiano, Garber, Alan J., Thomsen, Anne B., Furber, Sabina, Davies, Melanie
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Diabetes Association 2012
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3447855/ https://www.ncbi.nlm.nih.gov/pubmed/22851600 http://dx.doi.org/10.2337/dc11-2113

Ejemplares similares

One year of liraglutide treatment offers sustained and more effective glycaemic control and weight reduction compared with sitagliptin, both in combination with metformin, in patients with type 2 diabetes: a randomised, parallel-group, open-label trial
por: Pratley, R, et al.
Publicado: (2011)

GLP-1 Analogs and DPP-4 Inhibitors in Type 2 Diabetes Therapy: Review of Head-to-Head Clinical Trials
por: Gilbert, Matthew P., et al.
Publicado: (2020)

Protective effect of GLP-1 analog liraglutide on podocytes in mice with diabetic nephropathy
por: Shi, Shaomin, et al.
Publicado: (2023)

Triple Combination Therapy Using Metformin, Thiazolidinedione, and a GLP-1 Analog or DPP-IV Inhibitor in Patients with Type 2 Diabetes Mellitus
por: Kim, Sun Woo
Publicado: (2010)

A Physiologically‐Based Quantitative Systems Pharmacology Model of the Incretin Hormones GLP‐1 and GIP and the DPP4 Inhibitor Sitagliptin
por: Balazki, Pavel, et al.
Publicado: (2020)

Cost–utility analysis of liraglutide compared with sulphonylurea or sitagliptin, all as add-on to metformin monotherapy in Type 2 diabetes mellitus
por: Davies, M J, et al.
Publicado: (2012)

The Human GLP-1 Analog Liraglutide and the Pancreas: Evidence for the Absence of Structural Pancreatic Changes in Three Species
por: Nyborg, Niels C.B., et al.
Publicado: (2012)

GLP-1 Analog Liraglutide Improves Vascular Function in Polymicrobial Sepsis by Reduction of Oxidative Stress and Inflammation
por: Helmstädter, Johanna, et al.
Publicado: (2021)

Ertugliflozin plus sitagliptin versus either individual agent over 52 weeks in patients with type 2 diabetes mellitus inadequately controlled with metformin: The VERTIS FACTORIAL randomized trial
por: Pratley, Richard E., et al.
Publicado: (2018)

Sitagliptin, sitagliptin and metformin, or sitagliptin and amitriptyline attenuate streptozotocin-nicotinamide induced diabetic neuropathy in rats
por: Sharma, Ashish Kumar, et al.
Publicado: (2012)

GLP-1 Analogs, SGLT-2, and DPP-4 Inhibitors: A Triad of Hope for Alzheimer’s Disease Therapy
por: Złotek, Magdalena, et al.
Publicado: (2023)

Synergistic effects of metformin with liraglutide against endothelial dysfunction through GLP-1 receptor and PKA signalling pathway
por: Ke, Jing, et al.
Publicado: (2017)

Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin
por: Ahrén, Bo
Publicado: (2010)

The effect of liraglutide and sitagliptin on oxidative stress in persons with type 2 diabetes
por: Sivalingam, Suvanjaa, et al.
Publicado: (2021)

Efficacy and safety of liraglutide versus sitagliptin both in combination with metformin in patients with type 2 diabetes: A systematic review and meta-analysis
por: Li, Mingxing, et al.
Publicado: (2017)

Evaluating the Short-Term Cost-Effectiveness of Liraglutide Versus Sitagliptin in Patients with Type 2 Diabetes Failing Metformin Monotherapy in the United States
por: Langer, Jakob, et al.
Publicado: (2013)

Erratum. Renal Effects of DPP-4 Inhibitor Sitagliptin or GLP-1 Receptor Agonist Liraglutide in Overweight Patients With Type 2 Diabetes: A 12-Week, Randomized, Double-Blind, Placebo-Controlled Trial. Diabetes Care 2016;39:2042–2050
por: Tonneijck, Lennart, et al.
Publicado: (2019)

Improvement in glycated haemoglobin evaluated by baseline body mass index: a meta‐analysis of the liraglutide phase III clinical trial programme
por: Montanya, E., et al.
Publicado: (2016)

Safety, tolerability and sustained weight loss over 2 years with the once-daily human GLP-1 analog, liraglutide
por: Astrup, A, et al.
Publicado: (2012)

Induction of Energy Expenditure by Sitagliptin Is Dependent on GLP-1 Receptor
por: Goldsmith, Felicia, et al.
Publicado: (2015)

Addition of sitagliptin to ongoing metformin monotherapy improves glycemic control in Japanese patients with type 2 diabetes over 52 weeks
por: Kadowaki, Takashi, et al.
Publicado: (2012)

A 52‐week randomized controlled trial of ipragliflozin or sitagliptin in type 2 diabetes combined with metformin: The N‐ISM study
por: Kitazawa, Masaru, et al.
Publicado: (2021)

Spectroflourometric and Spectrophotometric Methods for the Determination of Sitagliptin in Binary Mixture with Metformin and Ternary Mixture with Metformin and Sitagliptin Alkaline Degradation Product
por: El-Bagary, Ramzia I., et al.
Publicado: (2011)

Liraglutide and DPP-4 inhibitors – side effects comparative clinical study
por: TIMOFTE, LUMINIŢA, et al.
Publicado: (2013)

Liraglutide relieves cardiac dilated function than DPP‐4 inhibitors
por: Hiramatsu, Takeyuki, et al.
Publicado: (2018)

Cost–benefit comparison of liraglutide and sitagliptin in the treatment of type 2 diabetes in Thailand
por: Deerochanawong, Chaicharn, et al.
Publicado: (2019)

The GLP-1 Analogs Liraglutide and Semaglutide Reduce Atherosclerosis in ApoE(−/−) and LDLr(−/−) Mice by a Mechanism That Includes Inflammatory Pathways
por: Rakipovski, Günaj, et al.
Publicado: (2018)

GLP-1 analog liraglutide-induced cardiac dysfunction due to energetic starvation in heart failure with non-diabetic dilated cardiomyopathy
por: Shiraki, Aya, et al.
Publicado: (2019)

Efficacy and Safety of Dulaglutide Versus Sitagliptin After 52 Weeks in Type 2 Diabetes in a Randomized Controlled Trial (AWARD-5)
por: Nauck, Michael, et al.
Publicado: (2014)

Efficacy and Safety Comparison of Liraglutide, Glimepiride, and Placebo, All in Combination With Metformin, in Type 2 Diabetes: The LEAD (Liraglutide Effect and Action in Diabetes)-2 study
por: Nauck, Michael, et al.
Publicado: (2009)

Saxagliptin but Not Sitagliptin Inhibits CaMKII and PKC via DPP9 Inhibition in Cardiomyocytes
por: Koyani, Chintan N., et al.
Publicado: (2018)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Liraglutide: A review of its therapeutic use as a once daily GLP-1 analog for the management of type 2 diabetes mellitus
por: Dharmalingam, Mala, et al.
Publicado: (2011)

The GLP-1 analog, liraglutide prevents the increase of proinflammatory mediators in the hippocampus of male rat pups submitted to maternal perinatal food restriction
por: Diz-Chaves, Y., et al.
Publicado: (2018)

Encapsulation in Polymeric Nanoparticles Enhances the Enzymatic Stability and the Permeability of the GLP-1 Analog, Liraglutide, Across a Culture Model of Intestinal Permeability
por: Ismail, Ruba, et al.
Publicado: (2019)

Liraglutide, Sitagliptin, and Insulin Glargine Added to Metformin: The Effect on Body Weight and Intrahepatic Lipid in Patients With Type 2 Diabetes Mellitus and Nonalcoholic Fatty Liver Disease
por: Yan, Jinhua, et al.
Publicado: (2019)

Improved Chromatographic Separation of Sitagliptin Phosphate and Metformin Hydrochloride
por: Hendy, Moataz S.
Publicado: (2015)

DPP-4 inhibitors and GLP-1RAs: cardiovascular safety and benefits
por: Razavi, Michael, et al.
Publicado: (2022)

Glucagon-Like Peptide-1 (GLP-1) Analog Liraglutide Inhibits Endothelial Cell Inflammation through a Calcium and AMPK Dependent Mechanism
por: Krasner, Nadia M., et al.
Publicado: (2014)

Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adults
por: van Can, J, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_14lf83ik739umq8kf1cbq4be8f